. Author manuscript; available in PMC: 2021 Mar 1.

Published in final edited form as: J Hum Genet. 2020 Sep 18;66(3):297–306. doi: 10.1038/s10038-020-00843-4

Table 3.

Pathway analysis based on pleiotropic genes

Pathway	Count	p value	Genes
hsa04080: neuroactive ligand-receptor interaction	8	2.53E–02	CRHR2, PTGER3, OPRL1, LEPR, GIPR, MTNR1B, MC4R, GRIN3A
hsa04930: type 2 diabetes mellitus	5	1.89E–03	MAPK1, SLC2A2, CACNA1G, KCNJ11, ABCC8
hsa04120: ubiquitin mediated proteolysis	5	7.00E–02	UBE2D3, FBXW7, UBE3C, UBE2E2, UBE2R2
hsa05216: thyroid cancer	4	4.17E–03	MAPK1, CCND1, PPARG, TCF7L2
hsa04520: adherens junction	4	5.69E–02	PTPRJ, MAPK1, PVRL2, TCF7L2
hsa05210: colorectal cancer	4	7.02E–02	MAPK1, CCND1, BCL2, TCF7L2
hsa05215: prostate cancer	4	8.04E–02	MAPK1, CCND1, BCL2, TCF7L2
hsa04950: maturity onset diabetes of the young	3	3.24E–02	HNF1B, HNF4A, SLC2A2
hsa05219: bladder cancer	3	8.24E–02	RPS6KA5, MAPK1, CCND1

All pathways are listed and sorted by the count of enriched pleiotropic genes. The corresponding p value and the specific genes are shown in the third and fourth columns. Most are metabolism-related pathways